ClinicalTrials.gov
public full text
Public Domain
A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors
This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of FDA022-BB05 for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2 overexpressing/expressing solid tumors which are not eligible for curative therapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors#862657
- HB1801 Combined Treatment of HER2-positive Breast Cancer#856813
- A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer#855003
- Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer#314329
- Breast Cancer Tumor Heterogeneity#966635
Record · ID 1464719
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive